Biotech and Pharmaceuticals


  • Healthcare Executives on a Saturday  Thursday, 15 Jan 2015 | 10:30 AM ET

    Healthcare executives talk about their weekend activities.

  • Biogen exec says he would trade places with Musk  Thursday, 15 Jan 2015 | 8:15 AM ET

    Healthcare industry executives name the CEOs they'd be most willing to trade places with.

  • Biopharma's challenges in 2015  Wednesday, 14 Jan 2015 | 9:30 AM ET

    Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.

  • Navellier’s crunching finds growth for cheap Wednesday, 14 Jan 2015 | 6:00 AM ET
    Actavis Group headquarters is shown in Hafnarfjordur, Iceland, April 20, 2006.

    Louis Navellier says crunching the numbers for stocks that move independent of the market point him to two drug companies and a Chinese retailer.

  • Chimerix tackles Ebola outbreak  Tuesday, 13 Jan 2015 | 11:46 AM ET

    Michelle Berrey, Chimerix CEO, discusses the testing of its Ebola drug Brincidofovir in a clinical setting in West Africa, with CNBC's Meg Tirrell.

  • Martha Stewart ordeal changed me: Sam Waksal Tuesday, 13 Jan 2015 | 11:24 AM ET
    Sam Waksal of Kadmon Pharmaceuticals

    "Any event in life changes one. That was an event that probably changed me in many ways. I think I am a better person," biotech company founder Sam Waksal.

  • Cigna's expansion strategy  Tuesday, 13 Jan 2015 | 10:17 AM ET

    David Cordani, Cigna president & CEO, weighs in on rival Aetna's wage plan and explains Cigna's growth strategy.

  • Sass bets on airline, hedge fund stock Monday, 12 Jan 2015 | 12:00 AM ET
    A ground crewmember prepares to push back an American Airlines Boeing 737-823 jet at a terminal at  Miami International Airport.

    Martin D. Sass' stock picks are trades in three popular sectors: airlines, pharmaceuticals and asset management.

  • Shire buys NPS Pharma in $5.2 billion deal Sunday, 11 Jan 2015 | 12:08 PM ET

    Shire said it will acquire NPS Pharmaceuticals in an all-stock transaction for about $5.2 billion, the companies said on Sunday.

  • Big deals, data kick off JPMorgan health conference Monday, 12 Jan 2015 | 1:04 AM ET

    The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.

  • How to play the JPMorgan health conference Friday, 9 Jan 2015 | 11:57 AM ET
    A chemist works in the lab of Ariad Pharmaceuticals.

    History says the best play is to buy biotech stocks the day before the JPMorgan meeting starts and hold until the end.

  • JPM's health care summit preview  Friday, 9 Jan 2015 | 9:45 AM ET

    CNBC biotech and pharma reporter Meg Tirrell looks at what to expect from the biggest and most important health care conference of the year. The 33rd annual J.P. Morgan Health Care Conference starts Monday, with 450 companies presenting to almost 9,000 attendees.

  • One man's mission to open doors for investors Friday, 9 Jan 2015 | 8:12 AM ET

    Biotech investor Brad Loncar is on a mission to persuade every presenting company at an upcoming biotech conference to also webcast its breakout session.

  • Biogen's anti-LINGO shows mixed results in study Thursday, 8 Jan 2015 | 12:44 PM ET

    Biogen Idec's anti-LINGO-1, showed promise in a mid-stage study in reversing the nerve damage associated with acute optic neuritis.

  • New antibiotic may conquer superbugs Wednesday, 7 Jan 2015 | 4:23 PM ET
    This black iChip was developed by researchers at Northeastern University to grow bacteria that usually don’t grow in the lab. They used it to get a potentially very powerful new antibiotic from bacteria living in this soil samples, from a field in Maine.

    A new family of powerful antibiotics may provide a weapon against the growing threat of drug-resistant superbugs. NBC News reports.

  • Flu boosts drug store sales, but others take a hit Wednesday, 7 Jan 2015 | 10:24 AM ET
    A woman receiving a flu vaccination in San Pablo, Calif.

    This year’s flu season is shaping up to be as bad as expected. That's good news for drug stores, but insurers and others could suffer.

  • J&J and Bavarian Nordic start Ebola vaccine tests Tuesday, 6 Jan 2015 | 5:03 AM ET
    Amanda Smith, graduate student from the University of Utah, holds a container with test material in a sealed lab with a non-infective forum of the Ebola virus to help discover a drug that is effective against a part of Ebola that is vulnerable to drugs, on October 14, 2014 in Salt Lake City, Utah.

    Johnson & Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic.

  • New diet pill makes your gut think it's full Monday, 5 Jan 2015 | 2:35 PM ET

    A new drug activates receptors in the intestine, tricking the body into thinking it has just eaten a meal.

  • Gilead fights back: CVS deal sends shares soaring Monday, 5 Jan 2015 | 1:05 PM ET
    Pedestrians walk by a CVS store in San Francisco.

    Gilead Sciences' hepatitis C drugs, Sovaldi and Harvoni, will get exclusive coverage on several plans from CVS/Caremark.

  • Drug pricing concerns? Not at Gilead Monday, 5 Jan 2015 | 10:41 AM ET
    A scientist at Gilead Sciences' laboratory in Foster City, Calif.

    Despite drug pricing concerns that weighed on Gilead Sciences' stock toward the end of December, the drugmaker started the year by raising prices.

Contact Biotech and Pharma


    Get the best of CNBC in your inbox

    Please choose a subscription
    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.


  • Dan Mangan is a reporter covering health care for CNBC.com.

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.